Stocks making the biggest moves midday: Hasbro, Northrop Grumman, Equifax, General Motors & more

Midday moves were mixed: Hasbro rose more than 5% after beating third-quarter expectations and raising its full-year revenue-growth outlook, while Equifax gained almost 12% on an adjusted EPS beat despite dialing back 2026 revenue guidance. GM fell nearly 7% despite beating expectations, raising free-cash-flow expectations and announcing a $20 billion buyback; GE Aerospace dropped 4% as free cash flow of $2.04 billion missed the $2.2 billion estimate. Dream Finders Homes completed its Beazer Homes acquisition, Arcus Biosciences shares rose more than 8% on trial data, and Solstice Advanced Materials gained 4% after the Financial Times reported that activist Starboard Value had built a stake.

Analysis

The cross-sectional signal is that investors are rewarding evidence of durable demand and penalizing cash conversion or a weaker forward revenue path more than headline EPS beats. That makes guidance quality—not the quarter’s beat/miss count—the key 1–3 month discriminator.

For GM, the buyback announcement did not offset the negative reaction to the outlook. A repurchase without a timetable offers less near-term demand support than an executed program; the stock’s reaction suggests investors want proof that cash generation survives the narrowed outlook. Verify the updated FCF bridge and repurchase cadence before treating weakness as an opportunity. For GE Aerospace, a guidance increase alongside an FCF shortfall raises a conversion question, not necessarily a demand problem: working capital, investment and delivery timing need to be separated on the call. A persistent FCF gap would matter more than the raised outlook.

EFX’s guidance reduction is a warning that a quarterly EPS beat may not protect the medium-term growth multiple; the market’s positive reaction could fade if management identifies broad-based weakness. Conversely, HAS’s raised outlook is more investable if growth is supported by sell-through rather than channel loading—verify inventory and cash flow. STLD’s backlog supports forward visibility, but weak margins mean volume alone is not bullish; pricing versus input costs is the test. NOC’s EPS/revenue divergence warrants checking whether the beat reflects repeatable operations. Arcus’s trial signal is clinically encouraging but remains event-driven; assess study design, durability and next regulatory milestones before capitalizing it as broad commercial value. DFH’s completed acquisition shifts focus to integration and leverage; the share move alone does not establish synergy capture. SOLS’s reported activist stake is unconfirmed in this account, so avoid underwriting a catalyst until disclosed.

Key Decisions for Investors

• GM: Do not buy solely on the buyback headline. Keep exposure light pending the FCF bridge and repurchase schedule; reconsider if subsequent guidance or cash-flow data stabilizes, and cut the thesis if FCF expectations deteriorate further.
• HAS: Prefer entry on consolidation rather than chasing the gap. Confirm the raised outlook is supported by sell-through and cash conversion; reverse the constructive view if inventory builds or guidance is walked back.
• GE: Watch, rather than trade the guidance increase in isolation. If the next update shows FCF recovering toward expectations without weakening the outlook, reassess; persistent cash shortfall is a reason to stay cautious.
• SOLS: Treat activist interest as an alert, not a confirmed catalyst. Wait for a company filing or corroborating disclosure before positioning; no verified stake or engagement would weaken the event thesis.
• EFX / STLD: Avoid extrapolating the EFX EPS beat or STLD backlog into durable growth until guidance and margin drivers are clearer. For EFX, track 2026 revenue commentary; for STLD, track realized pricing and margins against backlog.